REVIEW A drug for the treatment of type 2 diabetes. Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta-cells. This depolarizes the beta-cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
REFERENCES
[1]
Li L, Yang M, Li Z, Yan X, Guo H, Pan H, Liu H, Liao Y, Yang G (2012). Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes Obes Metab. 14(2):187-9. PMID 21895920.
[2]
Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH (2012). Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab. 14(2):130-8. PMID 21923736.
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
